Full Text View
Tabular View
No Study Results Posted
Related Studies
The Use of Galantamine and CDP-Choline to Treat Adults With Schizophrenia (STAR-1)
This study is currently recruiting participants.
Study NCT00509067   Information provided by National Institute of Mental Health (NIMH)
First Received: July 30, 2007   Last Updated: May 12, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Schizophrenia
More general conditions related to this trial
Mental Disorders
Schizophrenia and Disorders with Psychotic Features
Interventions listed in this trial
Galantamine
CDP-choline
Placebo
Additional drug interventions recognized in this trial
Aripiprazole
Choline
Cytidine Diphosphate Choline
Olanzapine
Quetiapine
Risperidone
Ziprasidone
More general drug interventions related to this trial
Antiemetics
Antilipemic Agents
Antimetabolites
Antipsychotic Agents
Autonomic Agents
Central Nervous System Agents
Central Nervous System Depressants
Cholinergic Agents
Cholinesterase Inhibitors
Dopamine Agents
Dopamine Antagonists
Enzyme Inhibitors
Gastrointestinal Agents
Lipotropic Agents
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Neurotransmitter Uptake Inhibitors
Nootropic Agents
Parasympathomimetics
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Psychotropic Drugs
Serotonin Agents
Serotonin Antagonists
Serotonin Uptake Inhibitors
Therapeutic Uses
Tranquilizing Agents
Sponsors listed in this trial
National Institute of Mental Health (NIMH)


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services